2. Protein Tyrosine Kinase/RTK
  3. VEGFR
  4. Efdamrofusp alfa

Efdamrofusp alfa  (Synonyms: IBI302)

Cat. No.: HY-P99905 Purity: 99.89%
COA
SDS
Technical Support

Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions.

For research use only. We do not sell to patients.

CAS No. : 2375661-82-6

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Efdamrofusp alfa Featured Recommendations:

Efdamrofusp alfa Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Efdamrofusp alfa

View All VEGFR Isoform Specific Products:

View All Isoforms
VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions[1].

In Vitro

Efdamrofusp alfa (0.135 mg/mL; 0, 6, 12, or 24 h) suppresses endothelial cell migration and tube formation[1].
Efdamrofusp alfa (0-1000 μg/mL) inhibits complement activation in vitro[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Efdamrofusp alfa Related Antibodies

Cell Migration Assay [1]

Cell Line: Human primary umbilical vein endothelial cell (HUVEC)
Concentration: 0.135 mg/mL
Incubation Time: 0, 6, 12, or 24 h
Result: Showed a 20.91% reduction in migration.
In Vivo

Efdamrofusp alfa (13.5 μg; 3 days) inhibits activation ofthe complement system in a mouse model oflaser-induced CNV[1].
Efdamrofusp alfa (1.35 mg; single intravitreal injection) shows favorable safety profiles and exhibited antiangiogenetic efficacy in a nonhuman primate laser-induced CNV model[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6J mice[1]
Dosage: 13.5 μg; 13.0 μg
Administration: 3 days; 7days
Result: Significantly reduced C3d deposition.
Reduced vascular leakage at 7 days after laser-induced injury.
Significantly suppressed CNV formation 7 days after laser-induced injury.
Reduced the concentrations of vitreous VEGF-A.
Animal Model: Rhesus monkeys[1]
Dosage: 1.35 mg
Administration: Single intravitreal injection
Result: Decreased the CNV leakage at 14 and 28 days and effectively reduced CNV volume 28 days.
Clinical Trial
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Molecular Weight

140.4 kDa

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Efdamrofusp alfa]
Shipping

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • FLT1 (fms-related tyrosine kinase 1, vascular endothelial growth factor receptor 1, VEGFR-1, VEGFR, FLT, FRT, vascular permeability factor receptor)domain 2 fragment (14-204)-KDR (kinase insert domain receptor, vascular endothelial growth factor receptor 2, VEGFR2, VEGF-R2, FLK1, CD309)domain 3 fragment (206-308)-IGHG1 Fc (Fragment constant (205-431))-CR1 (complement receptor type 1, C3b/C4b receptor, C3BR, Knops blood group, KN, CD35)fragment (1-192)
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Efdamrofusp alfa Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Efdamrofusp alfa2375661-82-6IBI302IBI 302IBI-302VEGFRVascular endothelial growth factor receptorfusion proteinVEGF isoformC3b/C4bneovascular age-related macular degeneration (nAMD)complementInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Efdamrofusp alfa
Cat. No.:
HY-P99905
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.